Does H2-receptor antagonist alter the renal function of cyclosporine-treated kidney grafts?
- 18 Downloads
Histamine-type 2 antagonists (H2-blockers) as represented by cimentidine have been shown to adversely affect renal allograft function, particularly when coadministered with cyclosporine, currently a major immunosuppressant. To determine whether or not a newer and more powerful H2-blocker, famotidine, would produce similar adverse effects, we assessed seven cyclosporine-treated renal allograft recipients with regard to changes in their renal function on or off the H2-blocker over a one-week period. Neither the administration nor withdrawal of famotidine (20–40 mg/day) resulted in any significant changes in serum creatine, BUN, urine output or cyclosporine trough levels, suggesting that famotidine can be safely administered as an H2-blocker to cyclosporine-treated renal allograft recipients.
Key Wordshistamine-type 2 antagonist kidney allograft cyclosporine famotidine
Unable to display preview. Download preview PDF.
- 5.Finklestein W, Isselbacher KJ. Drug therapy: cimetidine. N Engl J Med 1978; 229: 992–996.Google Scholar
- 8.Kumar A, Cleveland RP. Immunoregulatory effects of cimetidine: inhibition of suppressor cell effector functionin vivo. Immunopharm Immunotoxicol 1988; 10: 327–332.Google Scholar
- 15.Takagi T, Takeda M, Maeno H. Arch Int Pharmacoldyn Ther 1982; 256: 49–58.Google Scholar
- 16.Ohishi T, Sakiyama Y, Matsumoto S. Enhancement of the antibody response of human peripheral-blood mononuclear cells to sheep red-blood cells by the histamine H2-receptor antagonist famotidine. Igaku-no-ayumi 1988; 144: 581–582. (in Japanese with English Abst.)Google Scholar
- 19.Beveridge T. Pharmacokinetics and metabolism of cyclosporin A. In White DJG ed. Cyclosporin A. Amsterdam, Elsevier Biomedical Press, 1982: 45–75.Google Scholar